Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

Paul M. Barr, Stephen D. Smith, Mark J. Roschewski, Susan M. O’Brien, Jeff P. Sharman, Jason M. Melear, Priti Patel, Roser Calvo, Helen Yang, Stephen E. Spurgeon

Research output: Contribution to journalLetterpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)1728-1732
Number of pages5
JournalLeukemia and Lymphoma
Issue number7
StatePublished - 2022

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this